Abstracts tagged "Adverse events"

Abstract Number: 573 • 2015 ACR/ARHP Annual Meeting
Association Between Three Measures of Oral Glucocorticoid Exposure and Potential Adverse Events Among Patients with Rheumatoid Arthritis
Jennie Best¹, Amanda Farr², Gregory Lenhart², Khaled Sarsour¹, Marni Stott-Miller² and Yong Gil Hwang³, ¹Genentech, South San Francisco, CA, ²Truven Health Analytics, Cambridge, MA, ³Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Oral glucocorticoids are commonly used to treat rheumatoid arthritis (RA). However, their use may be associated with potential adverse events. Therefore, the objective was…
Abstract Number: 587 • 2015 ACR/ARHP Annual Meeting
Defining the Conditions Under Which Long-Term Glucocorticoid Treatment Has a Good Benefit-Risk Ratio
Cindy Strehl¹, Johannes W J Bijlsma², Maarten de Wit³, Maurizio Cutolo⁴, Raphaele Seror⁵, Kevin L. Winthrop⁶, Frank Buttgereit¹ and EULAR Task Force on Glucocorticoids, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Medical Humanities, VU Medical Centre, Amsterdam, Netherlands, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ⁵Department of Rheumatology, Assistance Publique–Hopitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France, ⁶Division of Infectious Diseases, Oregon Health and Science University, Portland, OR
Background/Purpose: Glucocorticoids (GC) are used to treat a wide range of inflammatory diseases including rheumatic and musculoskeletal diseases. EULAR recommendations on GC therapy are up…
Abstract Number: 619 • 2015 ACR/ARHP Annual Meeting
Long-Term Adverse Events after Daily Concomitant Treatment with 10mg Prednisone in the 2-Year Computer Assisted Management in Early Rheumatoid Arthritis Trial-II
Maria de Hair, Nicole IJff, Johannes Jacobs and Jacob van Laar, Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
On behalf of the Society for Rheumatology Research Utrecht (SRU) Background/Purpose: To investigate the frequency of long-term adverse events (AEs) in early rheumatoid arthritis (RA)…
Abstract Number: 884 • 2015 ACR/ARHP Annual Meeting
Patient Perceptions of Treatment with Glucocorticoids in ANCA-Associated Vasculitis
Joanna Robson¹, Susan Ashdown², Jill Dawson³, Ebony Easley⁴, Don Gebhart⁵, Katherine Kellom⁶, Georgia Lanier⁷, Nataliya Milman⁸, Jacqueline Peck⁹, Judy A. Shea¹⁰, Peter F. Cronholm⁴ and Peter A. Merkel¹¹, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ²NONE, Branbury, United Kingdom, ³Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁴Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ⁵NONE, Columbus, OH, ⁶PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ⁷NONE, Framingham, MA, ⁸Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ⁹NONE, Oxford, United Kingdom, ¹⁰Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, United Kingdom, ¹¹Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) comprise a group of multisystem diseases of the small blood vessels…
Abstract Number: 956 • 2015 ACR/ARHP Annual Meeting
The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Other Adverse Events
Joost Swart¹, Angela Pistorio², Francesca Bovis³, Ekaterina Alexeeva⁴, Michael Hofer⁵, Susan Nielsen⁶, Jordi Anton⁷, Alessandro Consolaro⁸, Violeta Vladislava Panaviene⁹, Valda Stanevicha¹⁰, Maria Trachana¹¹, Constantin Ailioaie¹², Florence Uettwiller¹³, Fabrizio De Benedetti¹⁴, Elena Tsitsami¹⁵, Berit Flato¹⁶, Pavla Dolezalová¹⁷, Tamás Constantin¹⁸, Troels Herlin¹⁹, Sylvia Kamphuis²⁰, Sujata Sawhney²¹, Despoina Maritsi²², Veronika Vargova²³, Luca Villa⁸, Chiara Pallotti⁸, Angelo Ravelli³, Alberto Martini²⁴, Nico Wulffraat²⁵, Nicolino Ruperto²⁶ and on behalf of for PRINTO, ¹Pediatric Rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²Servizio di Epidemiologia e Biostatistica, Istituto Giannina Gaslini, Genoa, Italy, ³Istituto Giannina Gaslini, Genoa, Italy, ⁴Rheumatology, Scientific Center of Children's Health of RAMS, Moscow, Russia, ⁵Pediatrie, Unité Romande de Rhumatologie Pédiatrique, Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ⁶Pediatric Rheumatology Unit, Juliane Marie Centret, Rigshospitalet, Copenhagen, Denmark, ⁷Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ⁸Pediatria II - Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ⁹Centre of Pediatrics, Vilnius University, Vilnius, Lithuania, ¹⁰Department of Paediatrics, Riga Stradins University, Riga, Latvia, ¹¹1st Department of Pediatrics, Aristotle University, Thessaloniki, Greece, ¹²II Pediatric Clinic, Private Medical Clinic, IASI, Romania, ¹³Unité d'Immunologie, Hématologie et Rhumatologie Pediatrique, Université Paris-Descartes, IMAGINE Institute, Hôpital Necker-Enfants Malades, Paris, France, ¹⁴Reumatologia, Ospedale Pediatrico Bambino Gesù, Roma, Italy, ¹⁵First Department of Pediatrics, Children Hospital Aghia Sophia, Athens, Greece, ¹⁶Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁷Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ¹⁸Unit of Paediatric Rheumatology, 2nd Dpt of Pediatrics, Semmelweis University, Budapest, Hungary, ¹⁹Department of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark, ²⁰Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²¹Paediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, ²²2nd Department of Academic Pediatrics, Athens Medical School, university of Athens, Athens, Greece, ²³1st Department of Paediatrics and Adolescent Medicine, Šafarik University and Children Faculty Hospital in Košice, Kosice, Slovakia, ²⁴Istituto G. Gaslini, Pediatria II, PRINTO, and University of Genoa, Genoa, Italy, ²⁵Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²⁶Istituto G. Gaslini, Pediatria II, PRINTO, Genoa, Italy
Background/Purpose: Treatment of juvenile idiopathic arthritis (JIA) has greatly changed in the past 15 years thanks to the introduction of biologic agents but little is…
Abstract Number: 1403 • 2015 ACR/ARHP Annual Meeting
Immune Related Adverse Events Associated with Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review of Case Reports
Noha Abdel-Wahab^1,2 and Maria E. Suarez-Almazor³, ¹Rheumatology & Rehabilitation Department, Assiut University Hospital, Egypt, Assiut, Egypt, ²The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, USA, Houston, TX, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Background: The recent discovery of the immune checkpoint blockade that targets the regulatory pathways in T cells to enhance antitumor immune responses has led…
Abstract Number: 1488 • 2015 ACR/ARHP Annual Meeting
Following the American College of Rheumatology Quality Guidelines Can Enhance the Safety of Rheumatoid Arthritis Patients Treated with Disease Modifying Drugs
Delfina Bur¹ and Humeira M. Badsha², ¹Dr. Humeira Badsha Medical Clinic, Dubai, United Arab Emirates, ²Rheumatology, Dr Humeira Badsha Medical Center, Dubai, United Arab Emirates
Background/Purpose: Adverse events (AEs) and serious adverse events (SAEs) from disease modifying drugs (DMARDs) for Rheumatoid Arthritis (RA) can result in significant morbidity and even…
Abstract Number: 1538 • 2015 ACR/ARHP Annual Meeting
Clinical Analysis of 30 Rheumatoid Arthritis Patients Complicated with Malignant Lymphoma, Especially Methotrexate-Related Lymphoproliferative Disorder
Takuma Tsuzuki Wada¹, Yuji Akiyama¹ and Toshihide Mimura², ¹Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Recently, methotrexate (MTX) has been considered as the anchor drug in the treatment of rheumatoid arthritis (RA). However, it has been reported that MTX…
Abstract Number: 1631 • 2015 ACR/ARHP Annual Meeting
Adverse Events to Biologic Agents in Elderly Patients with Rheumatoid Arthritis: Cohort with 13 Years of Follow-up
Zulema Rosales^1,2, Leticia Leon¹, Alejandro Gomez-Gomez², Lucía Arietti², Esperanza Pato Cour², José Luis Fernández Rueda¹, Juan A Jover² and Lydia Abasolo¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: After more than a decade using biological agents (BA), is widely known their efficacy in the treatment of Rheumatoid Arthritis (RA) and their relationship…
Abstract Number: 2109 • 2015 ACR/ARHP Annual Meeting
Racial Disparities in the Risk of Hospitalized Severe Allopurinol Hypersensitivity Syndrome – a US Nationwide Study (2009-2011)
Na Lu¹, Sharan K. Rai², Jeewoong Choi³ and Hyon K. Choi¹, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ³Massachusetts College of Pharmacy and Health Sciences, Boston, MA
Background/Purpose: Allopurinol is the leading choice of urate-lowering therapy for gout (>95% of treated cases); however, it is associated with the rare but potentially fatal…
Abstract Number: 468 • 2014 ACR/ARHP Annual Meeting
Identification of Baseline Risk Factors for Adverse Events in Certolizumab Pegol Treated Rheumatoid Arthritis Patients
Boulos Haraoui¹, John Wade², Marc de Longueville³, Pauline Ralston⁴ and Jeffrey R. Curtis⁵, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, University of British Columbia, and Vancouver General Hospital, Vancouver, BC, Canada, ³SA Global Medical Affairs, UCB Pharma, Brussels, Belgium, ⁴Giant Professional Ltd, London, United Kingdom, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Despite efficacy of anti-tumor necrosis factors (anti-TNFs) in treating chronic immune conditions, some patients (pts) report serious adverse events (SAEs) highlighting a need to…
Abstract Number: 71 • 2014 ACR/ARHP Annual Meeting
Prevalence of Pain Reporting in Different Ethnic Groups in the UK: Results from a Large Biobank
Marcus Beasley¹, Gareth T. Jones¹, Tatiana Macfarlane² and Gary J. Macfarlane¹, ¹Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²Dental School, University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: Very large epidemiological studies designed to investigate genetic and environmental influences on disease, known as ‘biobanks' can be used to look at associations between…
Abstract Number: 1838 • 2014 ACR/ARHP Annual Meeting
No Increased Risk of Developing a First Invasive Melanoma in Rheumatoid Arthritis Patients Treated with Biologics: Results of a Collaborative Project of 11 European Biologics Registers
Louise Mercer¹, Johan Askling², Pauline Raaschou³, William Dixon¹, Lene Dreyer⁴, Merete Lund Hetland⁵, Lene Mellemkjær⁶, Anja Strangfeld⁷, Angela Zink⁸, Florenzo Iannone⁹, Axel Finckh¹⁰, Jakub Zavada¹¹, Helena Canhao¹², Fernando Martins¹³, Xavier Mariette¹⁴, Jacques Morel¹⁵, Jacques-Eric Gottenberg¹⁶, Adele Green¹, Victoria Hernández¹⁷, Florence Tubach¹⁸, Piet van Riel¹⁹, Kimme Hyrich²⁰ and Joachim Listing⁷, ¹The University of Manchester, Manchester, United Kingdom, ²Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Copenhagen University Hospital at Gentofte, Gentofte, Denmark, ⁵On behalf of all Depts of Rheumatology in Denmark, DANBIO, Glostrup Hospital, Glostrup, Denmark, ⁶Virus, Lifestyle and Genes, The Danish Cancer Society, Copenhagen, Denmark, ⁷German Rheumatism Research Center, Berlin, Germany, ⁸German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ⁹Reumatologia Universita e Policlinico di Bari, Bari, Italy, ¹⁰Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ¹¹Charles University, Prague, Czech Republic, ¹²Rheumatology Research Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal, ¹³Instituto de Medicina, Universidade de Lisboa, Lisbon, Portugal, ¹⁴rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ¹⁵Universite´ Montpellier, Montpellier, France, ¹⁶Department of rheumatology CHU, Strasbourg, France, ¹⁷BIOBADASER Registry, Madrid, Spain, ¹⁸INSERM, Universite Paris Diderot, Paris, France, ¹⁹Radboud University Medical Centre, Nijmegen, Netherlands, ²⁰Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Swedish and Danish national biologics registers (*) have reported a possible increase in melanoma risk with TNF inhibitors. Since melanomas are uncommon, the association…
Abstract Number: 1800 • 2014 ACR/ARHP Annual Meeting
Objectively Measured Sedentary Behavior Is a Distinct Risk Factor from Low Moderate-to-Vigorous Activity in Predicting Subsequent Frailty: Evidence from Osteoarthritis Initiative
Jing Song¹, Lee A. Lindquist¹, Rowland W. Chang¹, Pamela A. Semanik², Linda S. Ehrlich-Jones³, Jungwha Lee⁴, Min-Woong Sohn¹ and Dorothy D. Dunlop¹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³Rehabilitation Institute of Chicago, Chicago, IL, ⁴Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Physical frailty represents a state of high vulnerability for adverse health outcomes including disability and mortality. Physical activity interventions to improve health have largely…
Abstract Number: 1319 • 2014 ACR/ARHP Annual Meeting
Safety of Rituximab in Treating Pediatric Rheumatologic Disease
Arunima Agarwal¹, Anusha Ramanathan² and Rhina Castillo³, ¹Pediatric Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ³Pediatric Rheumatology, Childrens Hospital Los Angeles, Los Angeles, CA
Background/Purpose Rituximab is a chimeric human/murine monoclonal antibody directed against the B cell specific antigen CD20. There is growing evidence that suggests Rituximab may also…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].